D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
EGRX holding history
Eagle Pharmaceuticals, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
EGRX overviewAll 13F holders of EGRXFull Q2 2026 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 15
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −54,625−100.0% | Sold out | Holders |
| Q3 2024 | 54,625 | $203.8K | <0.1% | −116,383−68.1% | Reduced | Holders |
| Q2 2024 | 171,008 | $957.6K | <0.1% | −48,803−22.2% | Reduced | Holders |
| Q1 2024 | 219,811 | $1.15M | <0.1% | +56,321+34.4% | Added | Holders |
| Q4 2023 | 163,490 | $855.1K | <0.1% | +53,490+48.6% | Added | Holders |
| Q3 2023 | 110,000 | $1.73M | <0.1% | −17,579−13.8% | Reduced | Holders |
| Q2 2023 | 127,579 | $2.48M | <0.1% | +39,635+45.1% | Added | Holders |
| Q1 2023 | 87,944 | $2.49M | <0.1% | +33,027+60.1% | Added | Holders |
| Q4 2022 | 54,917 | $1.61M | <0.1% | +1,023+1.9% | Added | Holders |
| Q3 2022 | 53,894 | $1.42M | <0.1% | −43,970−44.9% | Reduced | Holders |
| Q2 2022 | 97,864 | $4.35M | <0.1% | −17,813−15.4% | Reduced | Holders |
| Q1 2022 | 115,677 | $5.72M | <0.1% | +24,978+27.5% | Added | Holders |
| Q4 2021 | 90,699 | $4.62M | <0.1% | −1,404−1.5% | Reduced | Holders |
| Q3 2021 | 92,103 | $5.14M | <0.1% | −32,865−26.3% | Reduced | Holders |
| Q2 2021 | 124,968 | $5.35M | <0.1% | +16,807+15.5% | Added | Holders |
| Q1 2021 | 108,161 | $4.51M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.